invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
September 05, 2023 03:00 ET
|
invIOs GmbH
Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started;invIOs awarded up to...
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
August 07, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
July 27, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd line Hodgkin Lymphoma
June 16, 2023 07:00 ET
|
Tessa Therapeutics Ltd
Objective response observed in 9/10 patients and complete response observed in 7/10 patientsNo patients proceeded to autologous stem cell transplant (ASCT) as of data cut-off Well tolerated safety...
Monthly information on share capital and company voting rights
June 13, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
May 15, 2023 09:15 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 15, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated...
Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders
March 01, 2023 06:00 ET
|
Yasheng Group
San Jose, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders; Begins Raising Capital for our Subsidiary, Jove Pharmaceutics...
Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development
February 24, 2023 03:30 ET
|
Yasheng Group
San Jose, California, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development SAN JOSE, CA--(February 24, 2023) - Yasheng Group, (OTC:...
The CAR-T cell therapy market is projected to grow at an annualized rate of 23%, claims Roots Analysis
February 15, 2023 10:00 ET
|
Roots Analysis
London, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035 ” report to its list of offerings. CAR-T cell...
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
February 09, 2023 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...